In agreement with these findings, recent work profiling the expression of several forkhead proteins, including FOXG1, as a function of glioma patient survival concluded that forkhead proteins are attractive biomarkers of GBM and warrant further investigation of their roles in gliomagenesis (Robertson et al., 2015). This evidence concerns the gene FOXG1 and central nervous system cancer.